ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 9, 2016, Pages 2386-2396

  Alanio, Alexandre ^a,l   Hauser, Philippe M ^b,l   Lagrou, Katrien ^c,d   Melchers, Willem J G ^e   Helweg Larsen, Jannik ^f,l   Matos, Olga ^g,l   Cesaro, Simone ^h,l   Maschmeyer, Georg ^i,l   Einsele, Hermann ^j,l   Donnelly, J Peter ^e   Cordonnier, Catherine ^k,l   Maertens, Johan ^d,l   Bretagne, Stéphane ^a,l   Agrawal, Samir ^l   Kibbler, Christopher ^l   Pagliuca, Antonio ^l   Ward, Katherine ^l   Akova, Murat ^l   Herbrecht, Raoul ^l   Mallet, Vincent ^l   Ribaud, Patricia ^l   Aljurf, Mahmoud ^l   Averbuch, Dina ^l   Engelhard, Dan ^l   Berg, Thomas ^l   Cornely, Oliver ^l   Penack, Olaf ^l   van Boemmel, Florian ^l   von Lilienfeld Toal, Marie ^l   Blennow, Ola ^l   Ljungman, Per ^l   Bruggemann, Roger ^l   Donnelly, Peter ^l   Kullberg, Bart Jan ^l   Melchers, Willem ^l   Calandra, Thierry ^l   Hirsch, Hans ^l   Marchetti, Oscar ^l   Orasch, Christina ^l   Tissot, Frederic ^l   Castagnola, Elio ^l   Girmenia, Corrado ^l   Mikulska, Malgorzata ^l   Pagano, Livio ^l   Viscoli, Claudio ^l   De La Camara, Rafael ^l   Duarte, Rafael ^l   Munoz, Patricia ^l   Drgona, Lubos ^l   Hargreaves, Ruth ^m   Hubacek, Petr ^l   Kouba, Michal ^l   Racil, Zdenek ^l   Klyasova, Galina ^l   Pettrikos, George ^l   Roilides, Emmanuel ^l   Skiada, Anna ^l   Rizzi Puechal, Valérie ⁿ   Sinko, Janos ^l   Slavin, Monica ^l   Styczynski, Jan ^l   Tweddle, Lorraine ^o   Wood, Craig ^p   more..

^a HÔPITAL LARIBOISIÈRE   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^g INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^h Policlinico GB Rossi   (Italy)

ⁱ KLINIKUM ERNST VON BERGMANN   (Germany)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k HENRI MONDOR HOSPITAL   (France)

^l University Hospital Leuven ^*  (Poland)

^m Gilead Sciences   (United Kingdom)

ⁿ PFIZER INC   (United States)

^o Astellas   (United Kingdom)

^p LBNL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCAN; COTRIMOXAZOLE; DIHYDROPTEROATE SYNTHASE;

ADULT; ARTICLE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EPIDEMIC; EVIDENCE BASED MEDICINE; FOLLOW UP; GENE MUTATION; GENOTYPE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOFLUORESCENCE TEST; LUNG LAVAGE; MULTILOCUS SEQUENCE TYPING; NONHUMAN; PNEUMOCYSTIS PNEUMONIA; PRACTICE GUIDELINE; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; ADVERSE EFFECTS; COMPLICATION; HEMATOLOGIC NEOPLASMS; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PROCEDURES;

DIAGNOSTIC TESTS, ROUTINE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; STEM CELL TRANSPLANTATION; TRANSPLANT RECIPIENTS;

EID: 84992706118     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw156     Document Type: Article

References (113)

1. Cordonnier C, Cesaro S, Maschmeyer G et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; doi:10.1093/ jac/dkw155
2. Maertens J, Cesaro S, Maschmeyer G et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with hematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016; doi:10.1093/jac/dkw157
3. Alanio A, Desoubeaux G, Sarfati C et al. Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. Clin Microbiol Infect 2011; 17: 1531-7.
4. Botterel F, Cabaret O, Foulet F et al. Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients. J Clin Microbiol 2012; 50: 227-31.
5. To KKW, Hung IFN, Xu Tet al. Clinical significanceof Pneumocystis jirovecii in patients with active tuberculosis. Diagn Microbiol Infect Dis 2013; 75: 260-5.
6. Lamoth F, Cruciani M, Mengoli C et al. b-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 2012; 54: 633-43.
7. Arendrup MC, Bille J, Dannaoui E et al. ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia. Bone Marrow Transplant 2012; 47: 1030-45.
8. Marchetti O, Lamoth F, Mikulska M et al. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012; 47: 846-54.
9. Mikulska M, Furfaro E, Viscoli C. Biomarkers for diagnosis and follow-up of invasive candidiasis: a brief review of the ECIL recommendations. Curr Fungal Infect Rep 2012; 6: 192-7.
10. Skiada A, Lanternier F, Groll AH et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). J Antimicrob Chemother 2013; 98: 492-504.
11. Caliendo AM, Hewitt PL, Allega JM et al. Performance of a PCR assay for detection of Pneumocystis carinii from respiratory specimens. J Clin Microbiol 1998; 36: 979-82.
12. Cartwright CP, Nelson NA, Gill VJ. Development and evaluation of a rapid and simple procedure for detection of Pneumocystis carinii by PCR. J Clin Microbiol 1994; 32: 1634-8.
13. Galan F, Oliver JL, Roux P et al. Detection of Pneumocystis carinii DNA by polymerase chain reaction compared to direct microscopy and immunofluorescence. J Protozool 1991; 38: 199S-200S.
14. Huggett JF, Taylor MS, Kocjan G et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2008; 63: 154-9.
15. Jiancheng W, Minjun H, Yi-jun A et al. Screening Pneumocystis carinii pneumonia in non-HIV-infected immunocompromised patients using polymerase chain reaction. Diagn Microbiol Infect Dis 2009; 64: 396-401.
16. Leibovitz E, Pollack H, Moore T et al. Comparison of PCR and standard cytological staining for detection of Pneumocystis carinii from respiratory specimens from patients with or at high risk for infection by human immunodeficiency virus. J Clin Microbiol 1995; 33: 3004-7.
17. Moonens F, Liesnard C, Brancart F et al. Rapid simple and nested polymerase chain reaction for the diagnosis of Pneumocystis carinii pneumonia. Scand J Infect Dis 1995; 27: 358-62.
18. Rabodonirina M, Raffenot D, Cotte L et al. Rapid detection of Pneumocystis carinii in bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients: use of a simple DNA extraction procedure and nested PCR. J Clin Microbiol 1997; 35: 2748-51.
19. Roux P, Lavrard I, Poirot JL et al. Usefulness of PCR for detection of Pneumocystis carinii DNA. J Clin Microbiol 1994; 32: 2324-6.
20. Sing A, Trebesius K, Roggenkamp A et al. Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups. J Clin Microbiol 2000; 38: 1461-7.
21. Takahashi T, Goto M, Endo T et al. Pneumocystis carinii carriage in immunocompromised patients with and without human immunodeficiency virus infection. J Med Microbiol 2002; 51: 611-4.
22. Tia T, Putaporntip C, Kosuwin R et al. A highly sensitive novel PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveloar lavage specimens from immunocompromised patients. Clin Microbiol Infect 2012; 18: 598-603.
23. Zingale A, Carrera P, Lazzarin A et al. Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects. J Clin Microbiol 2003; 41: 2709-12.
24. Tamburrini E, Mencarini P, De Luca A et al. Diagnosis of Pneumocystis carinii pneumonia: specificity and sensitivity of polymerase chain reaction in comparison with immunofluorescence in bronchoalveolar lavage specimens. J Med Microbiol 1993; 38: 449-53.
25. Agostoni F, Atzori C, Angeli E et al. Pneumocystis carinii diagnosis: an update. Int J Antimicrob Agents 2000; 16: 549-57.
26. Skot J, Lerche AG, Kolmos HJ et al. Pneumocystis carinii in bronchoalveolar lavage and induced sputum: detection with a nested polymerase chain reaction. Scand J Infect Dis 1995; 27: 363-7.
27. Evans R, Joss AW, Pennington TH et al. The use of a nested polymerase chain reaction for detecting Pneumocystis carinii from lung and blood in rat and human infection. J Med Microbiol 1995; 42: 209-13.
28. Savoia D, Millesimo M, Cassetta I et al. Detection of Pneumocystis carinii by DNA amplification in human immunodeficiency virus-positive patients. Diagn Microbiol Infect Dis 1997; 29: 61-5.
29. Nevez G, Jounieaux V, Linas MD et al. High frequency of Pneumocystis carinii sp.f. hominis colonization in HIV-negative patients. J Eukaryot Microbiol 1997; 44: 36S.
30. Mathis A, Weber R, Kuster H et al. Simplified sample processing combined with a sensitive one-tube nested PCR assay for detection of Pneumocystis carinii in respiratory specimens. J Clin Microbiol 1997; 35: 1691-5.
31. Aderaye G,Woldeamanuel Y, Asrat D et al. Evaluation of Toluidine Blue O staining for the diagnosis of Pneumocystis jirovecii in expectorated sputum sample and bronchoalveolar lavage from HIV-infected patients in a tertiary care referral center in Ethiopia. Infection 2008; 36: 237-43.
32. Rohner P, Jacomo V, Studer R et al. Detection of Pneumocystis jirovecii by two staining methods and two quantitative PCR assays. Infection 2009; 37: 261-5.
33. Meliani L, Develoux M, Marteau-Miltgen M et al. Real time quantitative PCR assay for Pneumocystis jirovecii detection. J Eukaryot Microbiol 2003; 50 Suppl: 651.
34. McTaggart LR, Wengenack NL, Richardson SE. Validation of the MycAssay Pneumocystis kit for detection of Pneumocystis jirovecii in bronchoalveolar lavage specimens by comparison to a laboratory standard of direct immunofluorescence microscopy, real-time PCR, or conventional PCR. J Clin Microbiol 2012; 50: 1856-9.
35. Hauser PM, Bille J, Lass-Florl C et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol 2011; 49: 1872-8.
36. Flori P, Bellete B, Durand F et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing Pneumocystis jirovecii pneumonia from bronchoalveolar lavage specimens. J Med Microbiol 2004; 53: 603-7.
37. Fillaux J, Malvy S, Alvarez M et al. Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jirovecii pneumonia. J Microbiol Methods 2008; 75: 258-61.
38. Brancart F, Rodriguez-Villalobos H, Fonteyne P-A et al. Quantitative TaqMan PCR for detection of Pneumocystis jirovecii. J Microbiol Methods 2005; 61: 381-7.
39. Arcenas RC, Uhl JR, Buckwalter SP et al. A real-time polymerase chain reaction assay for detection of Pneumocystis from bronchoalveolar lavage fluid. Diagn Microbiol Infect Dis 2006; 54: 169-75.
40. Maschmeyer G, Helweg-Larsen J, Pagano L et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia (PcP) in non HIV-infected haematology patients. J Antimicrob Chemother 2016; doi:10.1093/jac/ dkw158.
41. Shorr AF, Susla GM, O'Grady NP. Pulmonary infiltrates in the non- HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. Chest 2004; 125: 260-71.
42. Cushion MT. Are members of the fungal genus Pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above? PLoS Pathog 2010; 6: e1001009.
43. Tamburrini E, Mencarini P, Visconti E et al. Imbalance between Pneumocystis carinii cysts and trophozoites in bronchoalveolar lavage fluid from patients with pneumocystosis receiving prophylaxis. J Med Microbiol 1996; 45: 146-8.
44. Cirioni O, Giacometti A, Barchiesi F et al. Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J Antimicrob Chemother 2000; 46: 577-82.
45. Wakefield AE, Pixley FJ, Banerji S et al. Detection of Pneumocystis carinii with DNA amplification. Lancet 1990; 336: 451-3.
46. Reid AB, Chen SCA, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 2011; 24: 534-44.
47. Fan LC, LuHW, Cheng KB et al. Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review. PLoS One 2013; 8: e73099.
48. Lu Y, Ling G, Qiang C et al. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol 2011; 49: 4361-3.
49. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-22.
50. Linssen CFM, Jacobs JA, Beckers P et al. Inter-laboratory comparison of three different real-time PCR assays for the detection of Pneumocystis jirovecii in bronchoalveolar lavage fluid samples. J Med Microbiol 2006; 55: 1229-35.
51. Montesinos I, Brancart F, Schepers K et al. Comparison of 2 real-time PCR assays for diagnosis of Pneumocystis jirovecii pneumonia in human immunodeficiency virus (HIV) and non-HIV immunocompromised patients. Diagn Microbiol Infect Dis 2015; 82: 143-7.
52. Dalpke AH, Hofko M, Zimmermann S. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii on the fully automated BD MAX platform. J Clin Microbiol 2013; 51: 2337-43.
53. Orsi CF, GennariW, Venturelli C et al. Performance of 2 commercial realtime polymerase chain reaction assays for the detection of Aspergillus and Pneumocystis DNA in bronchoalveolar lavage fluid samples from critical care patients. Diagn Microbiol Infect Dis 2012; 73: 138-43.
54. Sasso M, Chastang-Dumas E, Bastide S et al. Performances of four realtime PCR assays for the diagnosis of Pneumocystis jirovecii pneumonia. J Clin Microbiol 2016; 54: 625-30.
55. Pagano L, Pagliari G, Basso A et al. The role of bronchoalveolar lavage in the microbiological diagnosis of pneumonia in patients with haematological malignancies. Ann Med 1997; 29: 535-40.
56. Samuel CM, Whitelaw A, Corcoran C et al. Improved detection of Pneumocystis jirovecii in upper and lower respiratory tract specimens from children with suspected Pneumocystis pneumonia using real-time PCR: a prospective study. BMC Infect Dis 2011; 11: 329.
57. Helweg-Larsen J, Jensen JS, Benfield T et al. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol 1998; 36: 2068-72.
58. To KKW, Wong SCY, Xu T et al. Use of nasopharyngeal aspirate for diagnosis of Pneumocystis pneumonia. J Clin Microbiol 2013; 51: 1570-4.
59. Matos O, Costa MC, Lundgren B et al. Effect of oral washes on the diagnosis of Pneumocystis carinii pneumonia with a lowparasite burden and on detection of organisms in subclinical infections. Eur J Clin Microbiol Infect Dis 2001; 20: 573-5.
60. Mühlethaler K, Bögli-Stuber K, Wasmer S et al. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J 2012; 39: 971-8.
61. Guigue N, Alanio A, Menotti J et al. Utility of adding Pneumocystis jirovecii DNA detection in nasopharyngeal aspirates in immunocompromised adult patients with febrile pneumonia. Med Mycol 2015; 53: 241-7.
62. Baughman RP, Strohofer SS, Clinton BA et al. The use of an indirect fluorescent antibody test for detecting Pneumocystis carinii. Arch Pathol Lab Med 1989; 113: 1062-5.
63. Ng VL, Virani NA, Chaisson RE et al. Rapid detection of Pneumocystis carinii using a direct fluorescent monoclonal antibody stain. J Clin Microbiol 1990; 28: 2228-33.
64. Arasteh KN, Simon V, Musch R et al. Sensitivity and specificity of indirect immunofluorescence and Grocott-technique in comparison with immunocytology (alkaline phosphatase anti alkaline phosphatase=APAAP) for the diagnosis of Pneumocystis carinii in broncho-alveolar lavage (BAL). Eur J Med Res 1998; 3: 559-63.
65. Haeusler GM, Slavin MA, Seymour JF et al. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur J Haematol 2013; 91: 157-63.
66. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jirovecii during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol 2009; 36: 1600-5.
67. Mori H, Ohno Y, Ito F et al. Polymerase chain reaction positivity of Pneumocystis jirovecii during primary lung cancer treatment. Jpn J Clin Oncol 2010; 40: 658-62.
68. Louis M, Guitard J, Jodar M et al. Impact of HIV infection status on interpretation of quantitative PCR for detection of Pneumocystis jirovecii. J Clin Microbiol 2015; 53: 3870-5.
69. Robert Gangneux F, Belaz S, Revest M et al. Diagnosis of Pneumocystis jirovecii pneumonia in immunocompromised patients by real-time PCR: a 4-year prospective study. J Clin Microbiol 2014; 52: 3370-6.
70. Kushima H, Ishii H, Tokimatsu I et al. Effects of sulfamethoxazoletrimethoprim on airway colonization with Pneumocystis jirovecii. Jpn J Infect Dis 2015, in press.
71. Karageorgopoulos DE, Qu JM, Korbila IP et al. Accuracy of b-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect 2013; 19: 39-49.
72. Onishi A, Sugiyama D, Kogata Y et al. Diagnostic accuracy of serum 1,3-b-D-glucan for Pneumocystis jirovecii pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 2012; 50: 7-15.
73. Held J,Wagner D. b-D-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia. Clin Microbiol Infect 2011; 17: 1118-22.
74. Matsumura Y, Shindo Y, Iinuma Y et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011; 11: 76.
75. Sax PE, Komarow L, Finkelman MA et al. Blood (1-.3)-b-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011; 53: 197-202.
76. Watanabe T, Yasuoka A, Tanuma J et al. Serum (1--.3) b-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009; 49: 1128-31.
77. Yasuoka A, Tachikawa N, Shimada K et al. (1--.3) b-D-Glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3: 197-9.
78. Wood BR, Komarow L, Zolopa AR et al. Test performance of blood b-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS 2013; 27: 967-72.
79. Bishop LR, Kovacs JA. Quantitation of anti-Pneumocystis jirovecii antibodies in healthy persons and immunocompromised patients. J Infect Dis 2003; 187: 1844-8.
80. Gigliotti F, Harmsen AG,Wright TW. Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice. Infect Immun 2003; 71: 3852-6.
81. Choukri F, Menotti J, Sarfati C et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010; 51: 259-65.
82. de Boer MGJ, de Fijter JW, Kroon FP. Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients: a systematic review. Med Mycol 2011; 49: 673-80.
83. Cushion MT, Linke MJ, Ashbaugh A et al. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 2010; 5: e8524.
84. Choukri F, Aliouat EM, Menotti J et al. Dynamics of Pneumocystis carinii air shedding during experimental pneumocystosis. J Infect Dis 2011; 203: 1333-6.
85. Hauser PM. The development of a typing method for an uncultivable microorganism: the example of Pneumocystis jirovecii. Infect Genet Evol 2004; 4: 199-203.
86. Maitte C, Leterrier M, Le Pape P et al. Multilocus sequence typing of Pneumocystis jirovecii from clinical samples: how many and which loci should be used? J Clin Microbiol 2013; 51: 2843-9.
87. Le Gal S, Damiani C, Rouillé A et al. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012; 54: e62-71.
88. Rabodonirina M, Vanhems P, Couray-Targe S et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalized with HIV-infected patients. Emerg Infect Dis 2004; 10: 1766-73.
89. Lu JJ, Lee CH. Pneumocystis pneumonia. J Formos Med Assoc 2008; 107: 830-42.
90. Esteves F, Gaspar J, Marques T et al. Identification of relevant singlenucleotide polymorphisms in Pneumocystis jirovecii: relationship with clinical data. Clin Microbiol Infect 2010; 16: 878-84.
91. Esteves F, Montes-Cano MA, La Horra de C et al. Pneumocystis jirovecii multilocus genotyping profiles in patients from Portugal and Spain. Clin Microbiol Infect 2008; 14: 356-62.
92. Nahimana A, Blanc DS, Francioli P et al. Typing of Pneumocystis carinii f. sp. hominis by PCR-SSCP to indicate a high frequency of co-infections. J Med Microbiol 2000; 49: 753-8.
93. Ripamonti C, Orenstein A, Kutty G et al. Restriction fragment length polymorphism typing demonstrates substantial diversity among Pneumocystis jirovecii isolates. J Infect Dis 2009; 200: 1616-22.
94. Ma L, Kutty G, Jia Q et al. Analysis of variation in tandem repeats in the intron of the major surface glycoprotein expression site of the human form of Pneumocystis carinii. J Infect Dis 2002; 186: 1647-54.
95. Tsolaki AG, Miller RF, Underwood AP et al. Genetic diversity at the internal transcribed spacer regions of the rRNA operon among isolates of Pneumocystis carinii from AIDS patients with recurrent pneumonia. J Infect Dis 1996; 174: 141-56.
96. Helweg-Larsen J, Lee CH, Jin S et al. Clinical correlation of variations in the internal transcribed spacer regions of rRNA genes in Pneumocystis carinii f.sp. hominis. AIDS 2001; 15: 451-9.
97. Esteves F, Gaspar J, de Sousa B et al. Clinical relevance of multiple single-nucleotide polymorphisms in Pneumocystis jirovecii pneumonia: development of a multiplex PCR-single-base-extension methodology. J Clin Microbiol 2011; 49: 1810-5.
98. Hauser PM, Blanc DS, Sudre P et al. Genetic diversity of Pneumocystis carinii in HIV-positive and -negative patients as revealed by PCR-SSCP typing. AIDS 2001; 15: 461-6.
99. Gits-Muselli M, Peraldi M-N, de Castro N et al. New short tandem repeat-based molecular typing method for Pneumocystis jirovecii reveals intrahospital transmission between patients from different wards. PLoS One 2015; 10: e0125763.
100. Parobek CM, Jiang LY, Patel JC et al. Multilocus microsatellite genotyping array for investigation of genetic epidemiology of Pneumocystis jirovecii. J Clin Microbiol 2014; 52: 1391-9.
101. Beser J, Hagblom P, Fernandez V. Frequent in vitro recombination in internal transcribed spacers 1 and 2 during genotyping of Pneumocystis jirovecii. J Clin Microbiol 2007; 45: 881-6.
102. Alanio A, Gits-Muselli M, Mercier-Delarue S et al. Dviersity of Pneumocystis jirovecii during infection revealed by ultra-deep pyrosequencing. Front Microbiol 2016, in press.
103. Queener SF, Cody V, Pace J et al. Trimethoprim resistance of dihydrofolate reductase variants from clinical isolates of Pneumocystis jirovecii. Antimicrob Agents Chemother 2013; 57: 4990-8.
104. Ma L, Borio L, Masur H et al. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J Infect Dis 1999; 180: 1969-78.
105. Nahimana A, Rabodonirina M, Bille J et al. Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother 2004; 48: 4301-5.
106. Costa MC, Esteves F, Antunes F et al. Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal. J Antimicrob Chemother 2006; 58: 1246-9.
107. Costa MC, Helweg-Larsen J, Lundgren B et al. Mutations in the dihydropteroate synthase gene of Pneumocystis jirovecii isolates from Portuguese patients with Pneumocystis pneumonia. Int J Antimicrob Agents 2003; 22: 516-20.
108. Helweg-Larsen J, Benfield TL, Eugen-Olsen J et al. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999; 354: 1347-51.
109. Kazanjian P, Locke AB, Hossler PA et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 1998; 12: 873-8.
110. Matos O, Esteves F. Epidemiology and clinical relevance of Pneumocystis jirovecii Frenkel, 1976 dihydropteroate synthase gene mutations. Parasite 2010; 17: 219-32.
111. Hauser PM, Nahimana A, Taffé P et al. Interhuman transmission as a potential key parameter for geographical variation in the prevalence of Pneumocystis jirovecii dihydropteroate synthase mutations. Clin Infect Dis 2010; 51: e28-33.
112. Matos O, Esteves F. Pneumocystis jirovecii multilocus gene sequencing: findings and implications. Future Microbiol 2010; 5: 1257-67.
113. Costa J-M, Botterel F, Cabaret O et al. Association between circulating DNA, serum (1-.3)-b-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia. Clin Infect Dis 2012; 55: e5-8.